Fundz
A company that just raised surges hiring in 30 to 60 days. Fundz shows you the money, about a month before the job ad.See it live →

Q32 Bio Inc. Appoints New Chief Medical Officer and Chief Development Officer

PUBLIC · QTTBSep 14, 2026•about 2 hours ago

Position

Chief Development Officer

Company

Q32 Bio

Ellie Hershberger, Pharm.D.
WalthamBiotechnologyHealthcareHealth CareTherapeutics

Description

On September 14, 2026, Q32 Bio Inc. announced the appointments of José Trevejo, M.D., Ph.D. as Chief Medical Officer and Ellie Hershberger, Pharm.D

Company Information

Company

Q32 Bio

Location

Waltham, Massachusetts, United States

About

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Per the National Alopecia Areata Foundation, about 700,000 people in the United States live with alopecia areata, a disease which has a life-altering impact on patients and limited current treatment options. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

Don't miss Q32 Bio's next move

Get an email the moment Q32 Bio changes its leadership, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
Joel
Senior decision-maker at this company
••••••••@••••••••

See Joel's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Q32 Bio's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Q32 Bio changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.